CClinicalTrials.gg
CompletedNCT04439630Updated Oct 5, 2020

Effects of Nopal Fractions on Postprandial Glucose Regulation and Appetite Variables in Healthy Humans

An interventional study of Nopal fractions and Test product without the active components in Glucose Tolerance and Appetite Sensations, sponsored by Lund University. Completed at 1 site in Sweden. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-05.

Sponsored by Lund University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Postprandial effects of Nopal fractions on glucose and appetite regulation will be investigated in healthy humans, in a randomised controlled crossover trial

02

Conditions studied

  • Glucose Tolerance
  • Appetite Sensations

Keywords

  • healthy subjects
  • diabetes prevention
  • obesity prevention
03

In context

Lead sponsor

Lund University is the lead sponsor of 230 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy
  • non-smokers
  • diet accordance with the Nordic Nutrition Recommendations
  • BMI: 18.5-25 kg/m2

Exclusion criteria

Exclusion Criteria:

  • metabolic disorders
  • food allergies
  • no probiotics or other food /supplement which may interfere with the study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
24 participants (actual)

Study arms

  • Sham comparator
    reference

    Test product without the active components

    Dietary Supplement: Test product without the active components

  • Experimental
    Nopal fraction 1

    Fraction one out of two possible

    Dietary Supplement: Nopal fractions

  • Experimental
    Nopal fraction 2

    Fraction two out of two possible

    Dietary Supplement: Nopal fractions

Interventions

  • Dietary supplementNopal fractions

    Nopal flour were divided in two fractions and mixed in two different test breads

  • Dietary supplementTest product without the active components

    Test product without the active components

06

What researchers measure

Primary outcomes

  1. postprandial glucose tolerance

    effects on postprandial glucose tolerance after intake of test products at breakfast. Measurements were performed at fasting (time = 0 min) and at 15, 30, 45, 60, 90, 120, 150 and 180 min.

    Time frame: 0-180 min after start of the meal

  2. postprandial insulin concentrations

    effects on serum insulin concentrations after intake of test products at breakfast. Measurements were performed at fasting (time = 0 min) and at 15, 30, 45, 60, 90, 120, 150 and 180 min.

    Time frame: 0-180 min

Secondary outcomes

  1. subjective appetite variables

    Subjective appetite variables (hunger, satiety, desire to eat) after intake of test products at breakfast, using a 100 mm Visual Analogue Scale (VAS) on a white paper. Except from a center mark in the center of the scale there was no other visible marks. Measurements were performed at fasting (time = 0 min) and at 15, 30, 45, 60, 90, 120, 150 and 180 min.

    Time frame: 0-180 min

07

Study locations

1 site
  • Food Technology, engineering and Nutrition, LTH, Lund University
    Lund, 22100, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04439630
Lead sponsor
Lund University
Responsible party
Anne Nilsson (Associate professor, Lund University) — Principal investigator
First posted
Jun 19, 2020
Start date
Jul 1, 2020
Primary completion
Aug 1, 2020
Completion
Aug 1, 2020
Last update
Oct 5, 2020

Study contacts

Anne Nilsson, assoc. prof.
principal investigator · Lund University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion